Johnson & Johnson (J&J) has reported new 52-week data from the Phase III ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and ICONIC-LEAD trials, evaluating the safety and efficacy of Icotyde (icotrokinra), a once-daily oral pill for moderate-to-severe plaque psoriasis.
The Phase III trial results are being presented at the 2026 American Academy of Dermatology Annual Meeting.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In the ICONIC treatment groups, the proportion of patients achieving completely clear skin, defined as psoriasis area and severity index (PASI) 100, increased from 41% to 49% in ICONIC-ADVANCE 1, and from 33% to 48% in ICONIC-ADVANCE 2 between weeks 24 and 52.
Patients initially on placebo who switched to Icotyde at week 16 showed comparable clearance by week 52, 50% in ADVANCE 1 and 43% in ADVANCE 2.
The adverse event profile remained consistent throughout the study period, with overall adverse event and infection rates lower than those observed with deucravacitinib through week 24.
At week 52, nearly 60% of adolescents in the ICONIC-LEAD study achieved complete clearance, 86% reached PASI 90 response at one year, with 92% maintained this response from week 24 to 52. The incidence of adverse events did not increase over the one-year treatment period.
ICONIC-ADVANCE 1 & 2 randomised controlled trials compared Icotyde with placebo and deucravacitinib in moderate-to-severe plaque psoriasis. ICONIC-LEAD involved 684 participants aged 12 years or above.
J&J vice-president and immunodermatology and respiratory disease areas lead Liza O’Dowd said: “The Icotyde one-year data showcase what’s possible when targeted science meets real-world patient needs.
“Across age groups, high-impact disease sites, and in head-to-head trials, the results point to a new first-line systemic therapy that can move the needle on treatment gaps in plaque psoriasis.”
Earlier this month, J&J reported encouraging results from a Phase I study of the investigational intravesical drug-releasing system, Erda-iDRS (erdafitinib).
